| Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment (NCT07498478) | TransThera Sciences (Nanjing), Inc. | 2026-03-17 |
| Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations (NCT07328919) | TransThera Sciences (Nanjing), Inc. | 2026-01-01 |
| Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (NCT05948475) | TransThera Sciences (Nanjing), Inc. | 2023-12-20 |
| Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor (NCT06057571) | TransThera Sciences (Nanjing), Inc. | 2023-11-17 |
| A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies (NCT05683717) | TransThera Sciences (Nanjing), Inc. | 2023-03-30 |
| TT-00973-MS Tablets in Patients With Advanced Solid Tumors (NCT05673538) | TransThera Sciences (Nanjing), Inc. | 2023-01-01 |
| Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies (NCT05275504) | TransThera Sciences (Nanjing), Inc. | 2022-06-01 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT05253053) | TransThera Sciences (Nanjing), Inc. | 2022-04-13 |
| Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma (NCT04919642) | TransThera Sciences (Nanjing), Inc. | 2021-12-07 |
| A Phase 1 Study of TT-00920 in Healthy Subjects (NCT05355129) | TransThera Sciences (Nanjing), Inc. | 2021-11-03 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects (NCT05043792) | TransThera Sciences (Nanjing), Inc. | 2021-08-19 |
| Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors (NCT04830501) | TransThera Sciences (Nanjing), Inc. | 2021-07-12 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT04742959) | TransThera Sciences (Nanjing), Inc. | 2021-03-14 |
| Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers (NCT04705922) | TransThera Sciences (Nanjing), Inc. | 2020-12-29 |
| Phase I, First-In-Human Study of TT-00920 in Healthy Subjects (NCT04364789) | TransThera Sciences (Nanjing), Inc. | 2020-02-05 |
| Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer (NCT03654547) | TransThera Sciences (Nanjing), Inc. | 2019-01-08 |